Project Oncology®

Guest: Filipa Lynce, MD It’s very common for patients with inflammatory breast cancer (IBC) to present with no underlying palpable mass, which may cause some challenges for clinicians and patients. So what are some unique challenges associated with surgery in IBC and the risks of deescalating? Join Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Insti...

Guest: Filipa Lynce, MD Inflammatory breast cancer (IBC) is a rare disease that represents about two to three percent of all breast cancers and is challenging to diagnose. To improve diagnosis, researchers are working to validate a new proposed scoring system. Review the current research with Dr. Flipia Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute a...

Host: Pavani Chalasani, MD, MPH Guest: Jason A. Mouabbi, MD Invasive lobular carcinoma (ILC) is an understudied subtype that occurs in about 10 to 15 percent of breast cancer patients and is known to be difficult to detect by imaging. So how do we approach diagnosing and treating this subtype? Dr. Pavani Chalasani is joined by Dr. Jason Mouabbi, Assistant Professor of Medicine at the University of...

Host: Pavani Chalasani, MD, MPH Guest: Jose Pablo Leone, MD Breast cancer is the second most common cause of brain metastases. Given this prevalence, how can we identify the early signs and symptoms and treat patients with metastatic breast cancer accordingly? Here to dive further into this topic with Dr. Pavani Chalasani is Dr. Jose Pablo Leone, Director of the Program for Breast Cancer in Men at...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Sophia Humphreys, PharmD, MHA, BCBBS Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Direct...

Host: Pavani Chalasani, MD, MPH Guest: Gabriel N. Hortobagyi, MD Bone metastases are the most frequent site of metastatic spread for breast cancer, especially for the luminal subtypes, which are the most frequent types of breast cancer. Here to dive further into these therapies with Dr. Pavani Chalasani is Dr. Gabriel Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology i...

Host: Pavani Chalasani, MD, MPH Guest: Nick McAndrew, MD, MSCE How can ribociclib plus endocrine therapy help reduce recurrence in early breast cancer? That’s the exact question the NATALEE trial sought to answer, and here to discuss the results with Dr. Pavani Chalasani is Dr. Nicholas McAndrew, Assistant Professor in the Division of Hematology and Oncology at the UCLA David Geffen School of Medi...

Host: Pavani Chalasani, MD, MPH Guest: Colleen Bohnenkamp, PharmD, BCPS, BCOP In a recent study, investigators conducted a randomized trial to compare the efficacy and tolerability of a fixed dose of an oral chemotherapy drug on a 7/7 schedule. Here with Dr. Pavani Chalasani to discuss the results from the X-7/7 trial is Dr. Colleen Bohnenkamp, Oncology Clinical Pharmacist who specializes in women...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Priscilla Brastianos, MD Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor...

Guest: Vivek Subbiah, MD This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.

Host: Jacob Sands, MD Guest: Biagio Ricciuti, MD Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Can...

Host: Jacob Sands, MD Guest: Eleni Rettig, MD HPV is the leading cause of oropharynx cancers in the United States, but with no screening tools currently available, how we can detect this cancer in our patients? Host Dr. Jacob Sands speaks with a leader in the field, Dr. Eleni Rettig, an Assistant Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School, to share risk factors and...

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory Sepich-Poore, MD/PhD Results from a recent study detail the impact that fungi can have in human cancer tumors. What do we need to know? Mario Nacinovich speaks with one of the researchers, Dr. Gregory Sepich-Poore from UC San Diego, to dive further into these results and their impact on cancer therapeutics.

Host: Pavani Chalasani, MD, MPH Guest: Hope S. Rugo, MD, FASCO Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatmen...

Host: Jacob Sands, MD Guest: Edward B. Garon, MD, MS Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore da...

Host: Pavani Chalasani, MD, MPH Guest: Prof. David Cameron A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.

Host: Pavani Chalasani, MD, MPH Guest: Erika Hamilton, MD A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at...

Host: Pavani Chalasani, MD, MPH Guest: Kevin Kalinsky MD, MS CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher...

Host: Pavani Chalasani, MD, MPH Guest: Nan Chen, MD Immunotherapy is starting to make its way in breast cancer, especially triple-negative breast cancer. So how do we identify which of our patients are good candidates for this treatment? Joining Dr. Pavani Chalasani to share the most recent research on immunotherapy is Dr. Nan Chen, an Assistant Professor of Medicine at the University of Chicago.

Host: Pavani Chalasani, MD, MPH Guest: Seema A. Khan, MD Dr. Pavani Chalasani meets with Dr. Seema Khan, a Professor of Surgery and Interim Co-Vice Chair of Research at Northwestern Feinberg School of Medicine, to explore the role of surgery in metastatic breast cancer and take a look at the current treatment landscape.

Host: Jacob Sands, MD Guest: Maya Leiva, PharmD, BCOP What causes drug shortages in the U.S.? Joining Dr. Jacob Sands to answer this question and dive in to what physicians and pharmacists can do to prepare for future shortages is Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy spec...

Host: Jacob Sands, MD Guest: Maya Leiva, PharmD, BCOP Recognizing bias and improving diversity is critical for patient outcomes, especially within the field of oncology. To explore how we can improve care for both LGBTQ+ patients and employees within healthcare, Dr. Jacob Sands is joined by Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified b...

Host: Pavani Chalasani, MD, MPH Guest: Kevin Kalinsky MD, MS Chemotherapy is one of the most commonly used treatments for cancer—but it can lead to challenging side effects. So do all of our patients really need it? Joining Dr. Pavani Chalasani to discuss whether or not chemotherapy is the right choice for patients with hormone receptor-positive HER2-negative, node-positive breast cancer is Dr. Ke...

Host: Jacob Sands, MD Guest: Marie Wood, MD Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.

Host: Pavani Chalasani, MD, MPH Guest: Aditya Bardia, MD, MPH For patients with hormone receptor-positive HER 2-negative metastatic breast, treatment can be challenging. But what treatment options are available? Lead investigator from the EMERALD trial Dr. Aditya Bardia joins Dr. Pavani Chalasani to share his insights.